Novo-Nordisk A/S (NVO) Price and Market Data

Novo Nordisk A/S is the world’s leading diabetes care company, holding about one-third of the global branded diabetes treatment market. Headquartered in Denmark, it develops, manufactures, and markets a broad portfolio that includes human and modern insulins, injectable diabetes therapies such as GLP-1 treatments, oral antidiabetic medications, and obesity treatments. The company also operates a smaller biopharmaceutical business, accounting for less than 10% of revenue, focused on protein therapies for hemophilia and other conditions.